I-Mab (IMAB)
收市後：
- Reuters
UPDATE 2-Biotech firm I-Mab to divest China operations, shift focus to US
I-Mab said on Wednesday it has agreed to divest its operations and assets in China as part of its strategy to become a U.S.-focused biotech firm, sending the company's shares up nearly 11% in premarket trading. The company will sell its China unit, I-Mab Shanghai, to affiliate Hangzhou Co for up to $80 million, subject to certain regulatory and sales-based milestones. The move makes strategic sense, Cantor Fitzgerald analyst Louise Chen said, adding that the development came as a surprise.
- Insider Monkey
Ray Dalio on Potential US-China War and Rise of China
In this article, we discuss Ray Dalio on potential US China war and rise of China. If you want to skip our detailed discussion on the US China war and rise of China, head directly to Top 5 Chinese Stocks Bridgewater Associates is Selling. America’s position as a globally dominant force is under threat. Divisive politics, […]
- Insider Monkey
I-Mab (NASDAQ:IMAB) Q2 2023 Earnings Call Transcript
I-Mab (NASDAQ:IMAB) Q2 2023 Earnings Call Transcript August 17, 2023 Tyler Ehler: Good morning, everyone, and thank you for joining us this morning and for standing by. I’d like to take this opportunity to welcome you all to the I-Mab Biopharma Mid-Year 2023 Financial Results and Business Update Conference Call. My name is Tyler Ehler, […]
